Keros Therapeutics, Inc. (NASDAQ:KROS) Receives $20.50 Average Price Target from Brokerages

Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) have been assigned a consensus rating of “Hold” from the nine ratings firms that are currently covering the firm, MarketBeat reports. Two investment analysts have rated the stock with a sell recommendation, three have assigned a hold recommendation and four have given a buy recommendation to the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $20.50.

KROS has been the subject of a number of research reports. Leerink Partners decreased their price target on Keros Therapeutics from $30.00 to $23.00 and set an “outperform” rating for the company in a research note on Tuesday, August 4th. Weiss Ratings lowered Keros Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a report on Friday, May 15th. HC Wainwright restated a “buy” rating and set a $20.00 price objective on shares of Keros Therapeutics in a research note on Tuesday, August 4th. Zacks Research downgraded Keros Therapeutics from a “hold” rating to a “strong sell” rating in a report on Wednesday, July 29th. Finally, Wall Street Zen upgraded Keros Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 8th.

Keros Therapeutics Price Performance

NASDAQ KROS opened at $11.20 on Monday. The company has a market capitalization of $222.10 million, a price-to-earnings ratio of -3.03 and a beta of 0.99. Keros Therapeutics has a 12 month low of $9.69 and a 12 month high of $22.55. The company’s fifty day moving average price is $10.63 and its two-hundred day moving average price is $12.17.

Keros Therapeutics (NASDAQ:KROS) last released its earnings results on Monday, August 3rd. The company reported ($1.45) earnings per share for the quarter, missing the consensus estimate of ($1.34) by ($0.11). Keros Therapeutics had a negative return on equity of 21.40% and a negative net margin of 256.60%. As a group, analysts anticipate that Keros Therapeutics will post -5.12 EPS for the current year.

Insider Activity at Keros Therapeutics

In other Keros Therapeutics news, Director Julius Knowles sold 2,625 shares of Keros Therapeutics stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $10.73, for a total value of $28,166.25. Following the completion of the transaction, the director owned 10,958 shares of the company’s stock, valued at $117,579.34. The trade was a 19.33% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Nima Farzan sold 2,625 shares of the business’s stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $10.73, for a total transaction of $28,166.25. Following the sale, the director owned 9,767 shares of the company’s stock, valued at approximately $104,799.91. The trade was a 21.18% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 8,425 shares of company stock valued at $89,994. Corporate insiders own 12.60% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of KROS. Financial Management Professionals Inc. bought a new stake in shares of Keros Therapeutics during the 4th quarter valued at about $29,000. Caitong International Asset Management Co. Ltd lifted its holdings in Keros Therapeutics by 254.6% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,624 shares of the company’s stock worth $33,000 after acquiring an additional 1,166 shares during the last quarter. Tower Research Capital LLC TRC lifted its holdings in Keros Therapeutics by 149.2% in the second quarter. Tower Research Capital LLC TRC now owns 3,153 shares of the company’s stock worth $42,000 after acquiring an additional 1,888 shares during the last quarter. Lazard Asset Management LLC bought a new position in Keros Therapeutics in the first quarter worth about $129,000. Finally, New York State Common Retirement Fund boosted its stake in Keros Therapeutics by 264.1% in the second quarter. New York State Common Retirement Fund now owns 10,616 shares of the company’s stock valued at $142,000 after acquiring an additional 7,700 shares during the period. 71.56% of the stock is currently owned by institutional investors.

About Keros Therapeutics

Keros Therapeutics, Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.